Preliminary study results show significant improvement in dry eye questionnaire scores, subjective symptoms and corneal staining in patients with using 0.1% cyclosporine in chondroitin sulfate ophthalmic emulsion.
Cynthia Matossian, MD , FACS, ABES , and colleagues enrolled 75 patients older than 18 years with dry eye in this open-label registry study of Klarity-C (Imprimis).
In her presentation at the American Society for Cataract and Refractive Surgery meeting, Matossian said that while topical cyclosporine has been used to treat dry eye for years, some patients continue to struggle with cost, tolerability and lack of efficacy. She and her colleagues conducted this study to evaluate the efficacy and tolerability of a higher dose in a unique formulation.
Three-month results for 33 patients (76% female) with a mean age of 62 years (27 to 80 years old) indicated a mean change in Ocular Surface Disease Index (OSDI) scores from 39.99 pretreatment to 20.58 post-treatment (p <.001) and a mean change in corneal staining grade from 4.11 to 2.35.
This group of patients experienced marked improvements in OSDI score, with more than one-third scoring in the normal range; they experienced a statistically significant reduction in corneal staining; and patients were “happy with the tolerability and cost of medication,” Matossian reported.
She and her colleagues concluded in the study abstract that this treatment resulted in significant improvement in in OSDI scores, subjective symptoms and corneal staining, with a reduction in the irritation typically seen with other topical dry eye therapies. – by Nancy Hemphill, ELS, FAAO
Matossian C, et al. Tolerability and efficacy of topical 0.1% cyclosporine in chondroitin sulfate ophthalmic emulsion: An open-label registry study. Presented at: American Society of Cataract and Refractive Surgery annual meeting; May 3-7, 2019; San Diego.